Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 21, 2014; 20(23): 7347-7355
Published online Jun 21, 2014. doi: 10.3748/wjg.v20.i23.7347
Pediatric fatty liver disease: Role of ethnicity and genetics
Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Nicola Santoro
Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Department of Women and Children and General and Specialized Surgery, Seconda Università degli Studi di Napoli, 80138 Naples, Italy
Nicola Santoro, Department of Pediatrics, Yale University School of Medicine, New Haven, CT 06520, United States
Author contributions: The authors conceived and wrote the manuscript.
Supported by The American Heart Association (13SDG14640038) and 2012 Yale Center for Clinical Investigation cholar award to Santoro N; This publication was also made possible by CTSA Grant Number UL1 RR024139 from the National Center for Advancing Translational Science, a component of the National Institutes of Health (NIH), and NIH roadmap for Medical Research, Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH
Correspondence to: Nicola Santoro, MD, PhD, Department of Pediatrics, Yale University School of Medicine, 330 Cedar Street, PO Box 208064, New Haven, CT 06520, United States.
Telephone: +1-203-7376356 Fax: +1-203-7856421
Received: October 8, 2013
Revised: January 4, 2014
Accepted: January 20, 2014
Published online: June 21, 2014


Non-alcoholic fatty liver disease (NAFLD) comprehends a wide range of conditions, encompassing from fatty liver or steatohepatitis with or without fibrosis, to cirrhosis and its complications. NAFLD has become the most common form of liver disease in childhood as its prevalence has more than doubled over the past 20 years, paralleling the increased prevalence of childhood obesity. It currently affects between 3% and 11% of the pediatric population reaching the rate of 46% among overweight and obese children and adolescents. The prevalence of hepatic steatosis varies among different ethnic groups. The ethnic group with the highest prevalence is the Hispanic one followed by the Caucasian and the African-American. This evidence suggests that there is a strong genetic background in the predisposition to fatty liver. In fact, since 2008 several common gene variants have been implicated in the pathogenesis of fatty liver disease. The most important is probably the patatin like phospholipase containing domain 3 gene (PNPLA3) discovered by the Hobbs’ group in 2008. This article reviews the current knowledge regarding the role of ethnicity and genetics in pathogenesis of pediatric fatty liver.

Key Words: Non alcoholic fatty liver disease, Ethnicity, Patatin like phospholipase containing domain 3 gene, Obesity, Insulin resistance, Glucokinase regulatory protein, Apolipoprotein C3 gene, Farnesyl-diphosphate farnesyltransferase 1

Core tip: The prevalence of hepatic steatosis varies among different ethnic groups. Ethnicity with the greatest prevalence of non-alcoholic fatty liver disease (NAFLD) is the Hispanic one followed by Caucasian and then African-Americans. NAFLD exhibits tight links with insulin resistance and metabolic syndrome. Several gene variants have been so far identified by Genome Wide Association Studies or by a candidate gene approach as associated with fatty liver disease. The PNPLA3 rs738409 and the GCKR rs1260326 are the strongest variants associated with fatty liver in paediatrics.

Citation: Marzuillo P, Miraglia del Giudice E, Santoro N. Pediatric fatty liver disease: Role of ethnicity and genetics. World J Gastroenterol 2014; 20(23): 7347-7355

Non-alcoholic fatty liver disease (NAFLD) comprehends a wide range of conditions, encompassing from fatty liver or steatohepatitis (NASH) with or without fibrosis, to cirrhosis and its complications (e.g., hepatocellular carcinoma and portal hypertension )[1,2]. The NAFLD diagnostic criteria are similar in adults and children: infiltration of more than 5% of hepatocytes, as confirmed by liver histology, in patients with no or low daily alcohol utilization and in absence of either viral, autoimmune or drug-induced liver disease[3-5]. NAFLD has become the most relevant form of liver disease in childhood[6] and its prevalence has highly increased over the past 20 years because of the increased obesity prevalence in children. It currently affects between 3% and 11% of the pediatric population[7,8] reaching the rate of 46% among overweight and obese children and adolescents[6]. Therefore, the screening for NAFLD should be recommended to overweight and obese children[9-11]. The liver histology is the gold standard for NAFLD diagnosis, but to perform biopsies isn’t possible in all the cases. Liver enzymes values [aspartate aminotransferase (AST), and alanine aminotransferase (ALT)] are usually slightly elevated in children with steatosis without other causes of fatty liver[12]. Therefore, high serum AST and ALT levels, although they frequently do not well represent the grade of intrahepatic damage, are used as a non-invasive screening for pediatric NAFLD[13] along with liver ultrasound (US), that can detect the disease when steatosis involves > 20% of hepatocytes[14]. Although it does not represent the imaging gold standard, performing liver ultrasound has different advantages as screening : (1) relative cheapness; (2) massive expansion among pediatricians; and (3) practicability in the pediatric population[15]. Furthermore, very recently, in a large prospective pediatric cohort, it has been shown a good correlation between ultrasonographic steatosis score and the grade of fatty liver assessed by hepatic histology[14]. Computed tomography (CT) scan is not recommended in pediatric population because of the unjustifiable radiation related to the process. Magnetic resonance spectroscopy (MRS) and magnetic resonance Imaging (MRI) have been demonstrated to be the best methods to assess and quantify the amount of lipids present into the liver[16].

We reviewed the literature concerning the role of ethnicity and genetics in the pathogenesis of pediatric fatty liver disease.


Considering the global population in United States, Browning et al[17] described that the prevalence of NAFLD is the highest in the American Hispanic population (45%) and the lowest among African Americans (24%), with the Caucasians showing a midway prevalence (33%). The fatty liver prevalence in Europe, Australia, and Middle East encompasses from 20% to 30%[18]. On the basis of recent studies the NAFLD prevalence in Japan and China, such as Latin America, is comparable to the European prevalence (20%-30% in Japan and 15%-30% in China, respectively)[18]. In India, the fatty liver prevalence in urban populations encompasses from 16% to 32%; but in rural India, where there are traditional diets and lifestyles, the prevalence is lower (about 9%)[18]. About the prevalence of NAFLD in Africa there are few data. A Nigerian study estimated the prevalence to be about 9%[18]. This evidence suggests that a sedentary lifestyle and globalization of Western diet could be associated with an increase in the fatty liver prevalence in developing nations.


The principal risk factor for fatty liver in childhood is the obesity. In fact, the pediatric prevalence of NAFLD is particularly high in those countries where childhood obesity is widespread[6,19]. Pediatric NAFLD is also highly correlated with insulin resistance and type 2 diabetes mellitus[20,21]. A high percentage (from 20% to 80%) of children with NAFLD may show associated hypertriglyceridemia and high LDL levels[22]. The prevalence of NAFLD increases in pre-diabetic children, and the subjects affected by NASH have an higher grade of insulin resistance than the individuals with simple fatty liver[8]. The NAFLD can also affect very young children, but its prevalence is higher in adolescents[23]. In fact, sex hormones and insulin resistance in puberty[24,25] and, moreover, the increased propensity for unhealthy food choices and sedentary lifestyle typical of the adolescents[26] can justify the higher rate of NAFLD in adolescents. In all the ethnicity, NAFLD is more prevalent in boys than in girls[22] with a male to female ratio of 2:1. This may be explained by the liver-protective role of estrogens, as well as by the potentially negative role of androgens in aggravating NAFLD[27,28]. Another risk factor that can promote the development of fatty liver is the excessive fructose consumption, in particular the fructose contained in the most common soda[29]. Substantial links have been demonstrated between increased fructose consumption and obesity, dyslipidemia, and insulin resistance (IR). The link between fructose ingestion and NAFLD is mainly explained by an increased hepatic de novo lipogenesis[30].


The prevalence of hepatic steatosis varies among different ethnic groups. As previously shown, ethnicity with the greater prevalence is the Hispanic one followed by Caucasians and African-Americans[17]. NAFLD exhibits tight links with insulin resistance and metabolic syndrome (MS). It is, therefore, surprising that African-Americans, despite showing a similar or even higher degree of IR than Caucasians and Hispanics, have a lower prevalence of NAFLD[31] and a lower propensity for development of NASH[32]. The dissociation between fatty liver and insulin resistance in African-Americans suggests that this group is protected from hepatic fat accumulation even in presence of IR. Browning et al[17] demonstrated that the ethnic differences in the prevalence of hepatic steatosis were not due to differences in the presence of risk factors for NAFLD such as increased body mass index (BMI), reduced insulin sensivity or ethanol ingestion. On the other, although there are no differences in the prevalence of risk factors among ethnicities, there are evident differences in body fat distribution especially concerning the three major fat depots (intraperitoneal, abdominal subcutaneous, and lower extremity)[33]. In fact, African Americans tend to accumulate less intra-visceral fat, but more subcutaneous and mainly more gluteal fat than the other ethnic groups. Different is the association between regional adiposity and hepatic fat content. In fact, intra-peritoneal and lower extremities adiposity are strongly correlated with intra-hepatic fat, regardless of ethnicity[33].

While subjects with African ancestries have a low propensity to develop fatty liver, there are other ethnicities/races with a higher propensity to liver fat accumulation such as the subjects with Japanese descents. In fact, in a recent study, Azuma et al[34] considered ethnic difference in liver fat content among Japanese American in Hawaii, Japanese in Japan, and non-Hispanic whites in United States. Despite of a very similar BMI, compared with non Hispanic whites, Japanese-Americans had higher liver fat content which tended to become more significant with increasing BMI[34]. On the other hand, compared with Japanese, Japanese-Americans had a lower liver fat content, regardless of BMI[34].

What determines ethnic differences in hepatic steatosis is actually unknown.

In conclusion, insulin resistance and metabolic syndrome play a pivotal role in determining hepatic steatosis but they cannot explain such diversity among ethnic groups. In fact, as previously reported[17], the different ethnic predisposition to accumulate regional fat could partially explain the different ethnic prevalence of hepatic steatosis, since African-Americans have lower intraperitoneal fat accumulation than Hispanics and Caucasians. Therefore, the crucial issue to be resolved is why there is no association, in African-Americans, between the degree of IR and the degree of intra-hepatic fat. Is it possible that the hepatic steatosis does not play such an important role as we believe in developing IR? Why African-Americans despite high degree of IR have lower prevalence of NAFLD than other ethnic groups? Are there gene polymorphisms that could explain these paradoxes?

PNPLA3 rs738409

The most important gene involved in determining hepatic steatosis is the patatin like phospholipase containing domain 3 gene (PNPLA3). The PNPLA3 rs738409 single nucleotide polymorphism (SNP) is a non-synonymous variant, represented by a cytosine to guanosine substitution which encodes an isoleucine to methionine substitution at the amino acid position 148 (I148M) and was showed associated with NAFLD in a multiethnic cohort of adults[35] and children[36,37]. The PNPLA3 encodes for the adiponutrin an enzyme present in the liver and adipose tissue showing both a lipogenic and lipolytic activity in vitro. The prevalence of the PNPLA3 rs738409 minor allele (G) is 0.460 in Hispanics, 0.305 in Caucasians and 0.186 in African Americans[35].

It has been shown that this variant interacts with environmental factors (i.e., obesity[37,38] and alcohol consumption[39]) that can themselves promote steatosis. In fact, these stressors seem to reveal the association between the rs738409 minor allele (G) and hepatic damage in populations in whom it is otherwise hidden[40]. It is interesting to underline that the same interaction appears with some nutrients. Indeed, the total carbohydrate and high omega (n)-6 to n-3 polyunsaturated fatty acids (PUFA) ratio can enhance the association between steatosis and PNPLA3 variant[41].

Since the association between the PNPLA3 rs738409 and fatty liver has been shown[35], a few researches tried to demonstrate this association physiopathology. Probably, this variant may lead to a gain of function of the protein, which could act as a lipogenic factor[42]. In fact, there is evidence that, administrating the mutated PNPLA3 to knock-out mice for PNPLA3 through viral vectors[43,44], the knock-out mice obtain a higher susceptibility to fatty liver[42]. Consistently, it was also shown that sterol regulatory element binding transcription factor 1 (SREBP-1c), activated by carbohydrate feeding, transcriptionally activates PNPLA3 and other genes which encodes enzymes implicated in the fatty acid biosynthetic pathway[45]. Other researches demonstrating an interaction between the carbohydrates intake and the PNPLA3 rs738409 in developing of NAFLD appear to support this mechanism[41]. However, the lack of association of the PNPLA3 variant with increased plasma triglycerides is in contrast with this hypothesis[35,36].

Probably more interesting are the data deriving by evidence on the hydrolytic action of the PNPLA3 given that the PNPLA3 along with the acylglycerol transacetylase activity also has a triacylglycerol hydrolase function[46]. In fact, it has been recently showed that the rare allele could cause a lack of the PNPLA3 hydrolytic function[46] reducing the protein capacity in hydrolyzing the n-9 of about 15%[46]. The n-9 are the most common fatty acids deriving from the diet (meat, olive oil, sesame oil, almonds, and avocados) but they can derive also being synthesized from essential polyunsaturated fatty acids such as the n-6[47]. In addition, Perttila et al[48] demonstrated that the PNPLA3 148M allele significantly slows down the triglycerides hydrolysis and then increases the cellular accumulation of triglycerides in presence of an excess free fatty acids (FFA). This might also explain the association between the PNPLA3 variant and the dietary lipids in modulating liver injury[49]. More recently, Li et al[50], generating mutant PNPLA3 mice for I148M polymorphism, showed that the PNPLA3 variant is associated with an increased formation of fatty acids and triacylglycerol and relative depletion of triacylglycerol long-chain polyunsaturated fatty acids. Metabolic studies in the transgenic mice showed that high level expression of PNPLA3 I148M only in the liver and not in adipose tissue, affected both hepatic triacylglycerol (TAG) synthesis and catabolism. Also, it is interesting to note that PNPLA3 I148M transgenic mice develop steatosis on a sucrose diet but not on a high-fat diet[51].

Interestingly, Speliotes et al[52] showed, among patient selected for NAFLD, that the G allele of the PNPLA3 rs738409 polymorphism is associated with a favourable metabolic profile including decrease triglyceride levels, BMI, waist circumference and weight. These results argue strongly against rs738409 PNPLA3 polymorphism increasing risk of NAFLD indirectly through an effect of these components of metabolic syndrome[52]. Despite this evidence, the effect of this polymorphism on liver damage is driven by the amount of visceral fat[37], and it has been demonstrated that weight loss reduce the effect of this polymorphism in obese children[53]. For this reason, the possibility exists that the association between the PNPLA3 rs738409 SNP and NAFLD is modulated by the degree and the distribution of adiposity; this might explain the differences observed in the rs738409 PNPLA3 phenotype.

Therefore, the PNPLA3 I148M polymorphism increases the risk of NAFLD without a strong effect on metabolic syndrome components[52] but the abdominal fat, strictly correlated to metabolic syndrome components, can drive the effect of this polymorphism on liver damage. The weight loss, in fact, reduces the effect of this polymorphism[53].

GCKR rs1260326

Another gene that acts together with PNPLA3 in determining hepatic steatosis is the Glucokinase Regulatory Protein (GCKR) gene[54] which encodes for the glucokinase regulatory protein (GCKRP). The GCKRP inhibits the glucokinase (GCK) activity competing with the glucose, substrate of GCK[55-57]. The rs1260326 in the GCKR gene is a functionally relevant SNP consisting of a C to T substitution encoding for a proline-to-leucine substitution at position 446 (P446L). It has been demonstrated that the GCKRP L466 variant encodes for a protein that has decreased regulation by physiological concentration of fructose 6 phosphate. This results indirectly in a constant increased GCK activity[58]. The increase in GCK hepatic activity leads to enhancement of the glycolytic flux, and then promotes hepatic glucose metabolism and raises the concentrations of malonyl coenzyme A, a substrate for de novo lipogenesis (DNL). DNL may contribute for about 20% in liver fat accumulation[59]. The GCKR SNP rs1260326 minor allele (T) frequency was 0.466 in Caucasians, 0.129 in African Americans, and 0.355 in the Hispanics (P < 0.0001)[54]. This allele is associated with higher fat content in the liver among all ethnic groups[54]. Therefore, the possibility exists that the lowest prevalence of PNPLA3 rs738409 minor allele and GCKR rs1260326 minor allele (T) in African Americans could explain the lowest prevalence of hepatic steatosis in this ethnic group regardless of the unfavourable metabolic profile.

APOC3 rs2854116 and rs2854117

Apolipoprotein C3 gene (APOC3) variants are also involved, probably, in determining NAFLD. Petersen et al[60] showed that two SNPs in APOC3 (rs2854117 and rs2854116 codifying for C-482T and T-455C respectively) are associated with NAFLD and marked insulin resistance in 95 healthy, non-obese, Asian Indian men. The rare-allele carriers and wild-type homozygotes had a NAFLD prevalence of 38% and 0% respectively (P < 0.001). The subjects with NAFLD had marked insulin resistance[60]. The mechanism suggested was that the above mentioned APOC3 variants lead to higher plasma concentrations of apolipoprotein C3. The apolipoprotein C3 could then inhibit the lipoprotein lipase reducing the clearance of triglycerides. Consequence of reduced clearance of triglycerides is the increase of chylomicron-remnant particles that confer a predisposition to both fasting and postprandial hypertriglyceridemia. Higher circulating levels of chylomicron-remnant particles are then especially cleared by the liver through a receptor-mediated process[61-63], resulting in NAFLD and hepatic insulin resistance. Other data available in literature on correlation between APOC3 and NAFLD are contrasting[64,65]. The differences could be due to the anthropometric profile of subjects included in different researches. Petersen et al[60] studied a cohort without any risk factor of metabolic syndrome and with relatively lower body mass index (BMI) of 24.7 ± 3.6 and 24.1 ± 2.9 kg/m2 in Indian and non-Indian groups, respectively; it is important to underline that a BMI of 24.7 may indicate overweight in Indians but normal body weight in European. In comparison, other works studied larger numbers of subjects with overweight/obesity, dyslipidemia and with the criteria of metabolic syndrome.

FDFT1 rs2645424

A SNP in the farnesyl-diphosphate farnesyltransferase 1 (FDFT1) gene has been associated with the degree of liver injury: the rs2645424. This variant, in fact, has been showed to be associated with NAFLD activity score by a GWAS study. This study examined 236 non-Hispanic white women with fatty liver[66]. The FDFT1 gene, situated on chromosome 8, is an important modulator of cholesterol biosynthesis[67,68]. It codifies for the Squalene Synthase, an enzyme which converts two molecules of farnesyl pyrophosphate into squalene, a precursor to cholesterol. The rs2645424 is an intronic variant and therefore it is difficult to explain how it may affect the enzyme activity; an hypothesis could be that this SNP is in linkage disequilibrium with a variant in the promoter of squalene synthase gene that through the enhancement of its expression, could lead to an increased activation of the enzyme and to the intra-hepatic accumulation of cholesterol. Evidence in animals has, in fact, shown that transient over-expression of the FDFT1 gene in the liver of both wild-type and LDL Receptor knockout mice led to higher de novo cholesterol biosynthesis, over-secretion of cholesterol-rich LDL, increased cholesterol concentrations and a 37% enhancement in liver weight compared with controls related to hepatocyte proliferation[69]. This hypothesis would also be in agreement with recent researches demonstrating the role of intra-hepatic cholesterol accumulation in the pathogenesis of NASH[70].


More recently, more gene variants have been associated with fatty liver disease (Table 1), the mechanisms of action are summarized in Table 2.

Table 1 Gene variants associated with fatty liver disease identified by Genome Wide Association Studies.
Ref.GenePolymorphismsChromosomeNumber of subjects studied
Romeo et al[35]PNPLA3rs738409223383
Speliotes et al[71]GCKRrs126032627176
Petersen et al[60]APOC3rs285411611258
Speliotes et al[71]NCANrs2228603197176
Speliotes et al[71]LYPLAL1rs1213785517176
Speliotes et al[71]PPP1R3Brs424062487176
Adams et al[73]GCrs2220544928
Adams et al[73]LCP1rs732484513928
Adams et al[73]SLC38A8rs1186414616928
Adams et al[73]LPPR4rs127438241928
Kitamoto et al[72]SAMM50rs2143571221326
Kitamoto et al[72]PARVBrs6006473221326
Chalasani et al[66]FDFT1rs26454248236
Table 2 Proposed mechanism of action of each genetic variant associated with fatty liver disease.
GeneProposed mechanism of action
PNPLA3The PNPLA3 encodes for the adiponutrin, an enzyme expressed in the liver and adipose tissue showing both a lipogenic and lipolytic activity. This variant could cause both a gain of function of the enzyme (which could have a lipogenic activity in the liver) and a loss of function (that could predispose to steatosis by decreasing triglyceride hydrolysis in hepatocytes)
GCKRThe gene product is a regulatory protein that inhibits glucokinase in liver and pancreatic islet cells. The polymorphism could lead to increased hepatic glucokinase activity. This enhance the glycolytic flux and then promotes hepatic glucose metabolism and elevates the concentrations of malonyl coenzyme A, a substrate for de novo lipogenesis
APOC3APOC3 variants could increase the plasma concentrations of apolipoprotein C3. The apolipoprotein C3 could then inhibit the lipoprotein lipase reducing the clearance of triglycerides. Consequence of reduced clearance of triglycerides is the increase of chylomicron-remnant particles that confer a predisposition to both fasting and postprandial hypertriglyceridemia. Higher circulating levels of chylomicron-remnant particles are then especially cleared by the liver through a receptor-mediated process, resulting in NAFLD and hepatic insulin resistance
NCANNCAN encodes for a chondroitin sulfate proteoglycan thought to be involved in the modulation of cell adhesion and migration. NCAN is a risk factor for liver inflammation and fibrosis, suggesting that this locus is responsible for progression from steatosis to steatohepatitis
LYPLAL1LYPLAL1 encodes for a lysophospholipase and it is associated with increased hepatic steatosis probably preventing breakdown of triglycerides
PPP1R3BThis gene encodes the catalytic subunit of the serine/theonine phosphatase, protein phosphatase-1. The encoded protein is expressed in liver. It is associated with computer tomography–assessed liver attenuation but not histology-proven NAFLD
GCGC gene is expressed predominately in the hepatocytes where it encodes for VDBP. VDBP is the main vitamin D carrier, which has been implicated in the development of obesity and diabetes. In fact, low vitamin D concentrations could increase adipocyte intracellular calcium, stimulating lipogenesis, whereas vitamin D supplementation improves insulin resistance and down-regulates inflammatory cytokines such as tumor necrosis factor-a and interleukin-6 in cell models. Vitamin D levels are influenced by GC genetic polymorphisms
LCP1LCP-1 is an actin bundling protein expressed especially in hematopoietic cells and is involved in leukocyte activation and tumor cell proliferation. Its pathogenic role in NAFLD is unknown
SLC38A8 LPPR4SLC38A8 protein product is a putative sodium-coupled neutral amino acid transporter whose expression is limited to the brain, whereas LPPR4 catalyzes the dephosphorylation of biologically active lipids and is expressed especially in the hypothalamus. While the functional significance of neuronally expressed genes such as SLC38A8 and LPPR4 with NAFLD is not apparent, there is convincing evidence that the nervous system and particularly the hypothalamus play an important role in lipid homeostasis in the liver
SAMM50SAMM50 gene encodes for Sam50 a protein that may be involved in mitochondrial dysfunction. The subsequent decreased removal of reactive oxygen species could lead to progression of NAFLD
PARVBThe PARVB gene encodes parvin-b, which forms integrin-linked kinase-pinch-parvin complex. Integrins are a large family of heterodimeric cell surface receptors that act as mechanoreceptors by relaying information between cells and from the ECM to the cell interior. Since integrin receptors directly bind to ECM components to control remodeling, they are thought to play a crucial role in the evolution and progression of liver fibrosis. Overexpression of parvin-b leads to a concomitant increase in lipogenic gene expression
FDFT1The FDFT1 gene, situated on chromosome 8, is an important modulator of cholesterol biosynthesis[67,68]. It codifies for the Squalene Synthase, an enzyme which converts two molecules of farnesyl pyrophosphate into squalene, a precursor to cholesterol. An hypothesis could be that this SNP is in linkage disequilibrium with a variant in the promoter of squalene synthase gene that through the enhancement of its expression, could lead to an increased activation of the enzyme and to the intra-hepatic accumulation of cholesterol

Speliotes et al[71], in addition to GCKR, identified variants in novel loci NCAN and LYPLAL1 associated with both increasing computer tomography (CT) hepatic steatosis and histological NAFLD and identified variants in another locus, protein phosphatase 1 regulatory subunit 3B (PPP1R3B), associated with CT steatosis but not histologic NAFLD[71]. Recently Kitamoto et al[72] found that PNPLA3, sorting and assembly machinery component (SAMM50), parvin beta (PARVB) genetic regions was significantly associated with NAFLD in the Japanese population. Adams et al[73] showed that SNPs in two genes expressed in liver were associated with NAFLD adolescents: group-specific component (GC) and lymphocyte cytosolic protein-1 (LCP1). SNPs in two genes expressed in neurons were also associated with NAFLD: lipid phosphate phosphatise-related protein type 4 (LPPR4) and solute carrier family 38 member 8 (SLC38A8)[73].


Although the last few years have shed light in the pathogenesis of fatty liver, more researches are needed to be done and novel approaches to this problem are needed to be thought especially in the pediatric population. In fact, a limitation of this review is that several of the quoted studies have been performed in adults, but unfortunately accurate studies in pediatrics are quite limited also because the state of art techniques to assess hepatic fat content (MRI, MRS and liver biopsy) are difficult to perform in the pediatric population and very expensive.

One promising line of research that will allow to uncover novel mechanisms in the pathogenesis of fatty liver is the study of gut microbiome. Several lines of evidence, in fact, suggest a strong interaction between gut flora and liver. In fact, the liver receives 70% of its blood flow from the intestine through the portal vein and act as the first line of defence against gut-derived antigens, therefore it is one of the most exposed organs to gut-derived toxic factors[74]. The joint between gut microbiota and the development of fatty liver has been demonstrated both in murine model and in humans. In mice, Bäckhed et al[75] observed that the transplantation of normal caecal microbiota to germ-free mice induced, 15 d later, a 60% increase in body fat along with a more than two-fold increase in hepatic triglyceride content. For these reasons several researchers are now investigating the role of the gut flora in determining and influencing non-alcoholic fatty liver disease.


P- Reviewers: Chatterjee S, Makisalo H S- Editor: Wen LL L- Editor: A E- Editor: Liu XM

1.  Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, Goodman Z. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874-1882.  [PubMed]  [DOI]
2.  Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-1419.  [PubMed]  [DOI]
3.  Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S. ASH and NASH. Dig Dis. 2011;29:202-210.  [PubMed]  [DOI]
4.  Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195-203.  [PubMed]  [DOI]
5.  Aly FZ, Kleiner DE. Update on fatty liver disease and steatohepatitis. Adv Anat Pathol. 2011;18:294-300.  [PubMed]  [DOI]
6.  Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388-1393.  [PubMed]  [DOI]
7.  Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr. 2013;162:496-500.e1.  [PubMed]  [DOI]
8.  Giorgio V, Prono F, Graziano F, Nobili V. Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr. 2013;13:40.  [PubMed]  [DOI]
9.  Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut. 2009;58:1538-1544.  [PubMed]  [DOI]
10.  Barlow SE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120 Suppl 4:S164-S192.  [PubMed]  [DOI]
11.  August GP, Caprio S, Fennoy I, Freemark M, Kaufman FR, Lustig RH, Silverstein JH, Speiser PW, Styne DM, Montori VM. Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. J Clin Endocrinol Metab. 2008;93:4576-4599.  [PubMed]  [DOI]
12.  Nobili V, Reale A, Alisi A, Morino G, Trenta I, Pisani M, Marcellini M, Raucci U. Elevated serum ALT in children presenting to the emergency unit: Relationship with NAFLD. Dig Liver Dis. 2009;41:749-752.  [PubMed]  [DOI]
13.  Rodríguez G, Gallego S, Breidenassel C, Moreno LA, Gottrand F. Is liver transaminases assessment an appropriate tool for the screening of non-alcoholic fatty liver disease in at risk obese children and adolescents? Nutr Hosp. 2010;25:712-717.  [PubMed]  [DOI]
14.  Shannon A, Alkhouri N, Carter-Kent C, Monti L, Devito R, Lopez R, Feldstein AE, Nobili V. Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. J Pediatr Gastroenterol Nutr. 2011;53:190-195.  [PubMed]  [DOI]
15.  Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745-750.  [PubMed]  [DOI]
16.  Schwenzer NF, Machann J, Schraml C, Springer F, Ludescher B, Stefan N, Häring H, Fritsche A, Claussen CD, Schick F. Quantitative analysis of adipose tissue in single transverse slices for estimation of volumes of relevant fat tissue compartments: a study in a large cohort of subjects at risk for type 2 diabetes by MRI with comparison to anthropometric data. Invest Radiol. 2010;45:788-794.  [PubMed]  [DOI]
17.  Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395.  [PubMed]  [DOI]
18.  Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686-690.  [PubMed]  [DOI]
19.  Pacifico L, Poggiogalle E, Cantisani V, Menichini G, Ricci P, Ferraro F, Chiesa C. Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge. World J Hepatol. 2010;2:275-288.  [PubMed]  [DOI]
20.  Nadeau KJ, Klingensmith G, Zeitler P. Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase. J Pediatr Gastroenterol Nutr. 2005;41:94-98.  [PubMed]  [DOI]
21.  Manco M, Marcellini M, Devito R, Comparcola D, Sartorelli MR, Nobili V. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int J Obes (Lond). 2008;32:381-387.  [PubMed]  [DOI]
22.  Sundaram SS, Zeitler P, Nadeau K. The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr. 2009;21:529-535.  [PubMed]  [DOI]
23.  Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;28:13-24.  [PubMed]  [DOI]
24.  Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics. 2005;115:e561-e565.  [PubMed]  [DOI]
25.  Poustchi H, George J, Esmaili S, Esna-Ashari F, Ardalan G, Sepanlou SG, Alavian SM. Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. PLoS One. 2011;6:e21178.  [PubMed]  [DOI]
26.  Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology. 2009;50:1282-1293.  [PubMed]  [DOI]
27.  Lobanova YS, Scherbakov AM, Shatskaya VA, Evteev VA, Krasil’nikov MA. NF-kappaB suppression provokes the sensitization of hormone-resistant breast cancer cells to estrogen apoptosis. Mol Cell Biochem. 2009;324:65-71.  [PubMed]  [DOI]
28.  Xu JW, Gong J, Chang XM, Luo JY, Dong L, Jia A, Xu GP. Effects of estradiol on liver estrogen receptor-alpha and its mRNA expression in hepatic fibrosis in rats. World J Gastroenterol. 2004;10:250-254.  [PubMed]  [DOI]
29.  Vos MB, Kimmons JE, Gillespie C, Welsh J, Blanck HM. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med. 2008;10:160.  [PubMed]  [DOI]
30.  Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology. 2013;57:2525-2531.  [PubMed]  [DOI]
31.  Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427-436.  [PubMed]  [DOI]
32.  Santoro N, Feldstein AE, Enoksson E, Pierpont B, Kursawe R, Kim G, Caprio S. The association between hepatic fat content and liver injury in obese children and adolescents: effects of ethnicity, insulin resistance, and common gene variants. Diabetes Care. 2013;36:1353-1360.  [PubMed]  [DOI]
33.  Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology. 2009;49:791-801.  [PubMed]  [DOI]
34.  Azuma K, Curb JD, Kadowaki T, Edmundowicz D, Kadowaki S, Masaki KH, El-Saed A, Nishio Y, Seto TB, Okamura T. Ethnic difference in liver fat content: a cross-sectional observation among Japanese American in Hawaii, Japanese in Japan, and non-Hispanic whites in United States. Obes Res Clin Pract. 2013;7:e198-e205.  [PubMed]  [DOI]
35.  Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461-1465.  [PubMed]  [DOI]
36.  Santoro N, Kursawe R, D’Adamo E, Dykas DJ, Zhang CK, Bale AE, Calí AM, Narayan D, Shaw MM, Pierpont B. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology. 2010;52:1281-1290.  [PubMed]  [DOI]
37.  Giudice EM, Grandone A, Cirillo G, Santoro N, Amato A, Brienza C, Savarese P, Marzuillo P, Perrone L. The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat. PLoS One. 2011;6:e27933.  [PubMed]  [DOI]
38.  Romeo S, Sentinelli F, Dash S, Yeo GS, Savage DB, Leonetti F, Capoccia D, Incani M, Maglio C, Iacovino M. Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes (Lond). 2010;34:190-194.  [PubMed]  [DOI]
39.  Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet. 2010;42:21-23.  [PubMed]  [DOI]
40.  Romeo S, Huang-Doran I, Baroni MG, Kotronen A. Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Curr Opin Lipidol. 2010;21:247-252.  [PubMed]  [DOI]
41.  Davis JN, Lê KA, Walker RW, Vikman S, Spruijt-Metz D, Weigensberg MJ, Allayee H, Goran MI. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr. 2010;92:1522-1527.  [PubMed]  [DOI]
42.  Huang Y, He S, Li JZ, Seo YK, Osborne TF, Cohen JC, Hobbs HH. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci USA. 2010;107:7892-7897.  [PubMed]  [DOI]
43.  Chen W, Chang B, Li L, Chan L. Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology. 2010;52:1134-1142.  [PubMed]  [DOI]
44.  Basantani MK, Sitnick MT, Cai L, Brenner DS, Gardner NP, Li JZ, Schoiswohl G, Yang K, Kumari M, Gross RW. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res. 2011;52:318-329.  [PubMed]  [DOI]
45.  Pacifico L, Martino MD, Catalano C, Panebianco V, Bezzi M, Anania C, Chiesa C. T1-weighted dual-echo MRI for fat quantification in pediatric nonalcoholic fatty liver disease. World J Gastroenterol. 2011;17:3012-3019.  [PubMed]  [DOI]
46.  Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem. 2011;286:37085-37093.  [PubMed]  [DOI]
47.  Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood). 2008;233:674-688.  [PubMed]  [DOI]
48.  Perttilä J, Huaman-Samanez C, Caron S, Tanhuanpää K, Staels B, Yki-Järvinen H, Olkkonen VM. PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. Am J Physiol Endocrinol Metab. 2012;302:E1063-E1069.  [PubMed]  [DOI]
49.  Santoro N, Savoye M, Kim G, Marotto K, Shaw MM, Pierpont B, Caprio S. Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake. PLoS One. 2012;7:e37827.  [PubMed]  [DOI]
50.  Li JZ, Huang Y, Karaman R, Ivanova PT, Brown HA, Roddy T, Castro-Perez J, Cohen JC, Hobbs HH. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J Clin Invest. 2012;122:4130-4144.  [PubMed]  [DOI]
51.  Cohen AM, Teitelbaum A. Effect of glucose, fructose, sucrose and starch on lipgenesis in rats. Life Sci. 1968;7:23-29.  [PubMed]  [DOI]
52.  Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn JN. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology. 2010;52:904-912.  [PubMed]  [DOI]
53.  Marzuillo P, Grandone A, Perrone L, del Giudice EM. Weight loss allows the dissection of the interaction between abdominal fat and PNPLA3 (adiponutrin) in the liver damage of obese children. J Hepatol. 2013;59:1143-1144.  [PubMed]  [DOI]
54.  Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R, Dykas DJ, Bale AE, Giannini C, Pierpont B. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology. 2012;55:781-789.  [PubMed]  [DOI]
55.  Matschinsky FM. Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes. 1990;39:647-652.  [PubMed]  [DOI]
56.  Matschinsky FM. Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes. 2002;51 Suppl 3:S394-S404.  [PubMed]  [DOI]
57.  Slosberg ED, Desai UJ, Fanelli B, St Denny I, Connelly S, Kaleko M, Boettcher BR, Caplan SL. Treatment of type 2 diabetes by adenoviral-mediated overexpression of the glucokinase regulatory protein. Diabetes. 2001;50:1813-1820.  [PubMed]  [DOI]
58.  Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, Orho-Melander M, Gloyn AL. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet. 2009;18:4081-4088.  [PubMed]  [DOI]
59.  Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343-1351.  [PubMed]  [DOI]
60.  Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, Dziura J, Lifton RP, Shulman GI. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010;362:1082-1089.  [PubMed]  [DOI]
61.  Windler EE, Greeve J, Daerr WH, Greten H. Binding of rat chylomicrons and their remnants to the hepatic low-density-lipoprotein receptor and its role in remnant removal. Biochem J. 1988;252:553-561.  [PubMed]  [DOI]
62.  Nagata Y, Chen J, Cooper AD. Role of low density lipoprotein receptor-dependent and -independent sites in binding and uptake of chylomicron remnants in rat liver. J Biol Chem. 1988;263:15151-15158.  [PubMed]  [DOI]
63.  Weintraub MS, Eisenberg S, Breslow JL. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil. J Clin Invest. 1987;79:1110-1119.  [PubMed]  [DOI]
64.  Duseja A, Aggarwal R. APOC3 and PNPLA3 in non-alcoholic fatty liver disease: need to clear the air. J Gastroenterol Hepatol. 2012;27:848-851.  [PubMed]  [DOI]
65.  Hyysalo J, Stojkovic I, Kotronen A, Hakkarainen A, Sevastianova K, Makkonen J, Lundbom N, Rissanen A, Krauss RM, Melander O. Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2012;27:951-956.  [PubMed]  [DOI]
66.  Chalasani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S, Cui J, Taylor KD, Wilson L, Cummings OW. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology. 2010;139:1567-1576, 1576.e1-6.  [PubMed]  [DOI]
67.  Ness GC, Zhao Z, Keller RK. Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7 alpha hydroxylase. Arch Biochem Biophys. 1994;311:277-285.  [PubMed]  [DOI]
68.  Schechter I, Conrad DG, Hart I, Berger RC, McKenzie TL, Bleskan J, Patterson D. Localization of the squalene synthase gene (FDFT1) to human chromosome 8p22-p23.1. Genomics. 1994;20:116-118.  [PubMed]  [DOI]
69.  Okazaki H, Tazoe F, Okazaki S, Isoo N, Tsukamoto K, Sekiya M, Yahagi N, Iizuka Y, Ohashi K, Kitamine T. Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver. J Lipid Res. 2006;47:1950-1958.  [PubMed]  [DOI]
70.  Farrell GC, van Rooyen D. Liver cholesterol: is it playing possum in NASH? Am J Physiol Gastrointest Liver Physiol. 2012;303:G9-11.  [PubMed]  [DOI]
71.  Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Gudnason V, Eiriksdottir G, Garcia ME, Launer LJ. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7:e1001324.  [PubMed]  [DOI]
72.  Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, Teranishi H, Mizusawa S, Ueno T, Chayama K. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet. 2013;132:783-792.  [PubMed]  [DOI]
73.  Adams LA, White SW, Marsh JA, Lye SJ, Connor KL, Maganga R, Ayonrinde OT, Olynyk JK, Mori TA, Beilin LJ. Association between liver-specific gene polymorphisms and their expression levels with nonalcoholic fatty liver disease. Hepatology. 2013;57:590-600.  [PubMed]  [DOI]
74.  Compare D, Coccoli P, Rocco A, Nardone OM, De Maria S, Cartenì M, Nardone G. Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2012;22:471-476.  [PubMed]  [DOI]
75.  Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA. 2004;101:15718-15723.  [PubMed]  [DOI]